Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)

Stephen R. Mascioli; Richard H. Grimm; James D. Neaton; Jeremiah Stamler; Ronald J. Prineas; Jeffrey A. Cutler; Patricia J. Elmer; Robert McDonald; Harold Schnaper; James Schoenberger

doi:10.1016/0002-9149(90)90760-X

Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)

Stephen R. Mascioli, Richard H. Grimm, James D. Neaton, Jeremiah Stamler, Ronald J. Prineas, Jeffrey A. Cutler, Patricia J. Elmer, Robert McDonald, Harold Schnaper, James Schoenberger

Biostatistics

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

The Treatment of Mild Hypertension Study (TOMHS) is a randomized, double-blind clinical trial currently being conducted to compare the effects of nonpharmacologic therapy alone with those of 1 of 5 active drug regimens combined with nonpharmacologic therapy, for long-term management of patients with mild hypertension. Six classes of drugs were studied: (1) acebutolol (β blocker), (2) amlodipine (calcium antagonist), (3) chlorthalidone (diuretic), (4) dpxazosin (α₁ antagonist), (5) enalapril (angiotensin-converting enzyme inhibitor) and (6) placebo. All participants received nutritional-hygienic advice to reduce weight and sodium and alcohol intakes and to increase physical activity. End points include blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death, among participants receiving drugs as first-step treatment as well as nonpharmacologic treatment compared with incidence among those participants randomized to nonpharmacologic treatment only as the initial step.

Original language	English (US)
Pages (from-to)	C32-C35
Journal	The American Journal of Cardiology
Volume	66
Issue number	9
DOIs	https://doi.org/10.1016/0002-9149(90)90760-X
State	Published - Sep 25 1990

Bibliographical note

Funding Information:
From the Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota. This study is being supported in part by a grant from the National Heart, Lung, and Blood Institute, Beth&a, Maryland, and grants from Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp and Dohme, Pfizer Pharmaceuticals. and Wyeth-Aycrst Laboratories.

Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.

Access

10.1016/0002-9149(90)90760-X

Fingerprint Dive into the research topics of 'Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)'. Together they form a unique fingerprint.

Cite this

Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS). / Mascioli, Stephen R.; Grimm, Richard H.; Neaton, James D.; Stamler, Jeremiah; Prineas, Ronald J.; Cutler, Jeffrey A.; Elmer, Patricia J.; McDonald, Robert; Schnaper, Harold; Schoenberger, James.

In: The American Journal of Cardiology, Vol. 66, No. 9, 25.09.1990, p. C32-C35.

Research output: Contribution to journal › Article › peer-review

Mascioli, Stephen R. ; Grimm, Richard H. ; Neaton, James D. ; Stamler, Jeremiah ; Prineas, Ronald J. ; Cutler, Jeffrey A. ; Elmer, Patricia J. ; McDonald, Robert ; Schnaper, Harold ; Schoenberger, James. / Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS). In: The American Journal of Cardiology. 1990 ; Vol. 66, No. 9. pp. C32-C35.

@article{cbec841db24e443ebaee9e94105a86db,

title = "Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)",

abstract = "The Treatment of Mild Hypertension Study (TOMHS) is a randomized, double-blind clinical trial currently being conducted to compare the effects of nonpharmacologic therapy alone with those of 1 of 5 active drug regimens combined with nonpharmacologic therapy, for long-term management of patients with mild hypertension. Six classes of drugs were studied: (1) acebutolol (β blocker), (2) amlodipine (calcium antagonist), (3) chlorthalidone (diuretic), (4) dpxazosin (α1 antagonist), (5) enalapril (angiotensin-converting enzyme inhibitor) and (6) placebo. All participants received nutritional-hygienic advice to reduce weight and sodium and alcohol intakes and to increase physical activity. End points include blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death, among participants receiving drugs as first-step treatment as well as nonpharmacologic treatment compared with incidence among those participants randomized to nonpharmacologic treatment only as the initial step.",

author = "Mascioli, {Stephen R.} and Grimm, {Richard H.} and Neaton, {James D.} and Jeremiah Stamler and Prineas, {Ronald J.} and Cutler, {Jeffrey A.} and Elmer, {Patricia J.} and Robert McDonald and Harold Schnaper and James Schoenberger",

note = "Funding Information: From the Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota. This study is being supported in part by a grant from the National Heart, Lung, and Blood Institute, Beth&a, Maryland, and grants from Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp and Dohme, Pfizer Pharmaceuticals. and Wyeth-Aycrst Laboratories. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "1990",

month = sep,

day = "25",

doi = "10.1016/0002-9149(90)90760-X",

language = "English (US)",

volume = "66",

pages = "C32--C35",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)

AU - Mascioli, Stephen R.

AU - Grimm, Richard H.

AU - Neaton, James D.

AU - Stamler, Jeremiah

AU - Prineas, Ronald J.

AU - Cutler, Jeffrey A.

AU - Elmer, Patricia J.

AU - McDonald, Robert

AU - Schnaper, Harold

AU - Schoenberger, James

N1 - Funding Information: From the Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota. This study is being supported in part by a grant from the National Heart, Lung, and Blood Institute, Beth&a, Maryland, and grants from Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp and Dohme, Pfizer Pharmaceuticals. and Wyeth-Aycrst Laboratories. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 1990/9/25

Y1 - 1990/9/25

N2 - The Treatment of Mild Hypertension Study (TOMHS) is a randomized, double-blind clinical trial currently being conducted to compare the effects of nonpharmacologic therapy alone with those of 1 of 5 active drug regimens combined with nonpharmacologic therapy, for long-term management of patients with mild hypertension. Six classes of drugs were studied: (1) acebutolol (β blocker), (2) amlodipine (calcium antagonist), (3) chlorthalidone (diuretic), (4) dpxazosin (α1 antagonist), (5) enalapril (angiotensin-converting enzyme inhibitor) and (6) placebo. All participants received nutritional-hygienic advice to reduce weight and sodium and alcohol intakes and to increase physical activity. End points include blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death, among participants receiving drugs as first-step treatment as well as nonpharmacologic treatment compared with incidence among those participants randomized to nonpharmacologic treatment only as the initial step.

AB - The Treatment of Mild Hypertension Study (TOMHS) is a randomized, double-blind clinical trial currently being conducted to compare the effects of nonpharmacologic therapy alone with those of 1 of 5 active drug regimens combined with nonpharmacologic therapy, for long-term management of patients with mild hypertension. Six classes of drugs were studied: (1) acebutolol (β blocker), (2) amlodipine (calcium antagonist), (3) chlorthalidone (diuretic), (4) dpxazosin (α1 antagonist), (5) enalapril (angiotensin-converting enzyme inhibitor) and (6) placebo. All participants received nutritional-hygienic advice to reduce weight and sodium and alcohol intakes and to increase physical activity. End points include blood pressure change, side effects and quality-of-life indices; incidence of electrocardiographic and echocardiographic abnormalities; and incidence of cardiovascular clinical events, including death, among participants receiving drugs as first-step treatment as well as nonpharmacologic treatment compared with incidence among those participants randomized to nonpharmacologic treatment only as the initial step.

UR - http://www.scopus.com/inward/record.url?scp=0025130037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025130037&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(90)90760-X

DO - 10.1016/0002-9149(90)90760-X

M3 - Article

C2 - 2220647

AN - SCOPUS:0025130037

VL - 66

SP - C32-C35

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -

Characteristics of participants at baseline in the Treatment of Mild Hypertension Study (TOMHS)

Abstract

Bibliographical note

Access

Other files and links

Cite this